DeepMed Research

Prescient Therapeutics Ltd.

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: Public

Established: 1999-01-01

Employees: 1

Market Cap: -

Website: https://ptxtherapeutics.com/

Clinical Trials

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

Phase 2

Recruiting

Conditions: CTCL

Interventions: Drug: PTX-100

First Posted Date: 2025-03-25

Last Posted Date: 2025-04-03

Lead Sponsor: Prescient Therapeutics, Ltd.

Target Recruit Count: 115

Registration Number: NCT06854653

Locations: 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Virginia Commonwealth University Massey Comprehensive Cancer Cente, Richmond, Virginia, United States

and more 7 locations

Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort

Phase 1

Active, not recruiting

Conditions: Advanced Cancer
PTCL

Interventions: Drug: PTX-100

First Posted Date: 2019-04-03

Last Posted Date: 2025-04-11

Lead Sponsor: Prescient Therapeutics, Ltd.

Target Recruit Count: 25

Registration Number: NCT03900442

Locations: 🇦🇺
Epworth Healthcare, Melbourne, Victoria, Australia

A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia

Phase 1

Completed

Conditions: Acute Leukemia

Interventions: Drug: PTX-200
Drug: Cytarabine

First Posted Date: 2016-10-12

Last Posted Date: 2024-04-05

Lead Sponsor: Prescient Therapeutics, Ltd.

Target Recruit Count: 33

Registration Number: NCT02930109

Locations: 🇺🇸
University of Kansas Cancer Center, Fairway, Kansas, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer

Phase 1

Terminated

Conditions: Breast Adenocarcinoma
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer
Estrogen Receptor Positive
HER2/Neu Negative
Stage IIIC Breast Cancer
Stage IV Breast Cancer
Recurrent Breast Carcinoma
Stage IIB Breast Cancer

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Procedure: Therapeutic Conventional Surgery
Drug: Triciribine Phosphate

First Posted Date: 2012-10-02

Last Posted Date: 2020-09-24

Lead Sponsor: Prescient Therapeutics, Ltd.

Target Recruit Count: 34

Registration Number: NCT01697293

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States

PTX-200 and Carboplatin in Ovarian Cancer

Phase 1

Terminated

Conditions: Ovarian Cancer

Interventions: Drug: Triciribine
Drug: Carboplatin

First Posted Date: 2012-09-21

Last Posted Date: 2020-09-24

Lead Sponsor: Prescient Therapeutics, Ltd.

Target Recruit Count: 15

Registration Number: NCT01690468

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies

Phase 1

Completed

Conditions: Leukemia
Hematologic Malignancies

Interventions: Drug: Triciribine

First Posted Date: 2008-03-24

Last Posted Date: 2016-08-09

Lead Sponsor: Prescient Therapeutics, Ltd.

Target Recruit Count: 20

Registration Number: NCT00642031

Locations: 🇺🇸
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Phase I Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Subjects With Metastatic Cancer

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: Triciribine Phosphate Monohydrate

First Posted Date: 2006-08-15

Last Posted Date: 2016-08-09

Lead Sponsor: Prescient Therapeutics, Ltd.

Target Recruit Count: 19

Registration Number: NCT00363454

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Insitute, Tampa, Florida, United States

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy